Soligenix announces heightened stability for RiVax
by Nick Rees on February 4, 2010
Soligenix, Inc., has announced the publication of an article describing preclinical formulations of RiVax, a ricin toxin vaccine, with heightened stability.
The article, published in the February 2010 edition of Vaccine, was authored by Soligenix's collaborators at the University of Texas Southwestern Medical Center at Dallas, which originated the vaccine.
RiVax is currently under evaluation in Phase 1 human safety and immunogenicity trials as well as non-human primate trials for efficacy.
In this latest study, which was meant to establish preliminary conditions for long term stability to avoid the use of a cold chain, a series of formulations of RiVax, a modified recombinant ricin A chain protein, were examined for comparative effects of storage at room temperature versus refrigeration.
One combination, designed with excipients expected to add to protein stability and processed by lyophilization to remove water, was found to result in a vaccine retaining immunogenicity in animals for one year at room temperature.
"We know that the ricin subunit vaccine itself is very sensitive to denaturation, and we are very encouraged to find lyophilization conditions that aid in the long-term stability of the vaccine," Dr. Ellen Vitetta, director of the Cancer Immunobiology Center at UT Southwestern and an author of the study, said. "We are also pleased to see that in our study storage for over one year at ambient conditions resulted in no apparent degradation of potency or the integrity of the protein immunogen."
The lead formulation in the study showed no evidence of degradation while control formulations aggregated when reconstituted with water.
"These results are very promising not only for the future development of RiVax in particular, but also for the potential development of other vaccines with long-term stability, especially those using conventional adjuvants composed of aluminum salts," Robert N. Brey, Ph.D., chief scientific officer of Soligenix, said.
More News
- Bangladesh faces another anthrax outbreak
- Anthrax found in dead English heroin user
- Bangladesh says anthrax outbreak is under control
- Bioterror experts meet in Kansas City, Missouri
- Achaogen receives BARDA contract to fight biowarfare agents
- Israel begins prepping for biological, chemical attacks
- Anthrax confirmed in Russia's Republic of Dagestan
- Purdue receives grant to identify pathogens in food
- Fla. man convicted of threatened biological weapon use
- IDF to release updated chemical attack treatment handbook
Read all news
Browse by Category
Browse by Location
Search
Subscribe to our newsletter
RSS Feed
